Financial Results
Transpact Enterprises Reports H1 FY27 Results
Transpact Enterprises approved unaudited standalone financial results for the half year ended September 30, 2026, with the auditor’s limited review report.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Investor Presentation
Q2 FY26
Bearish
6
Neutral
4
Bullish
4
Bearish
11
Neutral
16
Bullish
19
Bearish
5
Neutral
12
Bullish
15
Bearish
5
Neutral
12
Bullish
15
Bearish
5
Neutral
12
Bullish
15
Bearish
5
Neutral
12
Bullish
15
Transpact Enterprises Ltd (TRANSPACT) is currently trading at 105.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Transpact Enterprises Limited is a listed Indian company whose core business is capital markets services including equity broking, investment advisory, portfolio management and digital trading solutions; additionally the company has developed proprietary therapeutic healthcare products (Vestibulator, Vestibulator Chair) and a cloud-based rehabilitation software product called Rehabsoft, indicating a hybrid services-and-products model. The company reported modest half-year revenue of Rs.9.50 lakhs and a profit before tax of Rs.4.94 lakhs for the period ended 30 September 2025, delivering positive earnings per share of Rs.0.13; the statutory auditor issued an unmodified review report and the board approved the unaudited results on 14 November 2025. Balance sheet dynamics show relatively high cash and bank balances of Rs.62.19 lakhs alongside inventories of Rs.54.95 lakhs, implying a cash-rich position relative to operating scale but with significant working capital tied up in inventory; short-term borrowings declined to Rs.5.89 lakhs while reserves increased to Rs.11.42 lakhs. Strategically, Transpact is diversified beyond financial services into medical device and SaaS offerings — Vestibulator and Rehabsoft — which create a potential new revenue vertical but disclosure is limited on commercialization, customer traction, and scale, leaving execution risk and go-to-market clarity as near-term focus areas.
Over the past 52 weeks, Transpact Enterprises Ltd has traded between a low of ₹81.47 and a high of ₹234.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Transpact Enterprises Ltd has a market capitalization of approximately 4.09. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Transpact Enterprises Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 51.13 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 4.09 Cr, Transpact Enterprises Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Transpact Enterprises Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Transpact Enterprises Ltd is 51.13. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Healthcare Equipment & Supplies
Medical Equipment & Supplies
4 Cr
Low Risk
51.1
60.1
0.1
7.7
234.90
81.47
Sales CAGR
Profit CAGR
ROE
ROCE